skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report

Download your free infographic today and tap into a sample of the essential information found in Outlook Reports from Biomedtracker.

This vital infographic contains critical data about catalysts for AEVI-001 for Attention Deficit Hyperactivity Disorder (ADHD) (Aevi Genomic Medicine, Inc. (GNMX)), and SAGE-217 for Major Depressive Disorder (MDD), (SAGE Therapeutics (SAGE)), including:

  • The catalyst that occurred
  • Trial results
  • Biomedtracker’s Likelihood of Approval (LOA) analysis
  • 5-day stock performance surrounding the catalyst event
  • Other notable upcoming catalysts for the drugs
  • Reactions from SAGE and Aevi Genomic


Don’t miss this free resource from the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide. Download the Catalyst Roundup from Biomedtracker today.